Webinar | Radiation Therapy| April 13, 2016

Using TomoTherapy for Complex Cases of Gynecological Cervix Cancer

Webinar sponsored by Accuray

The Webinar "Using TomoTherapy for Complex Cases of Gynecological Cervix Cancer" explains how to use the TomoTherapy radiation therapy system for treating difficult cases of gynecological cervix cancer. This webinar occurred May 26, 2016. 

Register for the archive version of this webinar

Statement of Purpose/Need:

Dr. Marjory Jolicoeur, chief radiation oncologist at Hôpital Charles Lemoyne, will share how they use the TomoTherapy system for treating difficult cases of gynecological cervix cancer.

 

Learning Objectives:

• To learn the indications of extended field radiotherapy and concomitant boost for uterine cervix cancer
• To learn how to treat uterine cervix cancer with extended field radiotherapy on the TomoTherapy system
• To learn the benefits of using the TomoTherapy System for concomitant boost
• To understand the benefits of the TomoTherapy planning on sparing organs at risk

 

Speakers:

Dr. Marjory Jolicoeur, M.D.
Hôpital Charles LeMoyne
Centre Hospitalier de l’Université de Sherbrooke
Greenfield Park, QC, Canada

After completing her radiation oncology residency in 1996 at the Université de Montréal, Jolicoeur completed a fellowship specializing in brachytherapy at the Centre George-François Leclerc in Dijon, France. She then started a professorship at the Department of Radiation Oncology of the Université de Montréal, which she still holds today. In 1999 she was appointed to the planning and construction of a new radiation oncology department for the Hôpital Charles Lemoyne, of which she currently serves as chief of department. 

As a brachytherapy specialist, Jolicoeur is active in the treatment of gynecological, genitourinary, breast, head and neck and soft tissue tumor. She has special research interests in the application of brachytherapy in area such as breast, genitourinary and gynecologic cancers. She is a strong promoter for the use of brachytherapy to replace the conventional mastectomy for local recurrences of breast cancer. 

Today, her main focus is the development of image guided implant procedures, the precision delivery of conformal high dose rate brachytherapy and teaching brachytherapy in the radiation-oncology program and it’s gynecologic oncology fellowship program.

 

About Accuray

Accuray is a radiation oncology company that develops, manufactures and sells precise innovative treatment solutions which set the standard of care, with the aim of helping patients live longer, better lives. The company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy. Their vision: A future where the fear, pain and suffering of cancer are a thing of the past. Their mission: To develop personalized, leading-edge treatment solutions that help cancer patients live longer, better lives.

 

Register for the archive version of this webinar

Related Content

News | PACS | June 23, 2017
Medidata and Median Technologies announced a new collaboration to streamline the growth and use of medical imaging in...
Therapixel Wins the Digital Mammography Challenge
News | Mammography | June 23, 2017
June 23, 2017 — French radiology technology company Therapixel was recently named the winner of the Digital Mammograp
ASTRO Issues Guideline for Stereotactic Radiation Use in Early-Stage Lung Cancer
Feature | Lung Cancer | June 23, 2017
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical guideline for the use of...
MRI Plus Mammography Improves Detection of New Breast Cancer After Surgery
News | Breast Imaging | June 22, 2017
A new article published by JAMA Oncology compares outcomes for combined mammography and magnetic resonance imaging (MRI...
University of Wisconsin-Madison Partners With RaySearch on RayCare OIS
News | Oncology Information Management Systems (OIMS) | June 21, 2017
The Department of Human Oncology at the University of Wisconsin-Madison has entered into an agreement with RaySearch to...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Henry Ford Cancer Institute First in World to Install Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 19, 2017
The Henry Ford Cancer Institute is the first in Michigan – and first in the world – to offer patients advanced...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Versa

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
Overlay Init